Business - onset.to

October 8, 2026

Helus Pharma kündigt Investorenpräsentation zu HLP003 und HLP004 für Depressionen und Angststörungen am 21. Oktober 2026 an

ir.helus.com · Oct 8, 2026

Article Business Industry Research DE

September 26, 2026

Kapitalismus-Crash, Cash und Psychedelika: Investor Christian Angermayer über Exit, Gehirnchips und Bitcoin

welt.de · Sep 26, 2026 · Holger Zschäpitz, Nando Sommerfeldt, WELT

Podcast Business Industry Mainstream DE

September 21, 2026

Cybin CEO Michael Halstead reports purchasing 100,000 common shares at a weighted average price of $13.4705

ir.helus.com · Sep 21, 2026 · Michael Halstead

Article Business Industry

How J&J's Spravato launch created the clinic infrastructure Compass needs for its potential COMP360 psychedelic rollout

biopharmadive.com · Sep 21, 2026 · Jacob Bell

Psilocybin Ketamine Article Business +2

September 14, 2026

Definium Therapeutics reports second positive Phase 3 trial of LSD candidate DT120 for generalised anxiety disorder

psychedelicalpha.com · Sep 14, 2026

LSD Article Business Clinical Research

September 10, 2026

Optimi Health sells reimbursed natural psilocybin in Australia while funding a 200-participant Canadian depression trial

behavioralwire.com · Sep 10, 2026 · Behavioral Wire Staff

Psilocybin Article Business Industry Research

September 1, 2026

Numinus Wellness Inc. files fiscal 2026 interim reports and seeks revocation of its British Columbia cease trade order

investors.numinus.com · Sep 1, 2026

Article Business Industry Policy

August 26, 2026

A Closer Look at Definium's Phase 3 LSD for Generalised Anxiety Disorder Readout and DT120's Efficacy

psychedelicalpha.com · Aug 26, 2026

LSD Article Business Clinical Research

LSD Has the Smallest Patent Pipeline, While Definium Leads Trials With Only One Granted Patent

altitude-online.com · Aug 26, 2026 · Nathan Richardson

LSD Article Business Industry Policy

August 24, 2026

Entropy Neurodynamics requests an ASX trading halt ahead of a significant U.S. Phase 2 clinical trial update with Robin Carhart-Harris

tipranks.com · Aug 24, 2026 · /news/author/tipranksaustraliannewsdesk

Article Business Clinical Industry

The 5-MeO-DMT Patent Race Has a Twist: The Clinical Leader Barely Owns Any of It

altitude-online.com · Aug 24, 2026 · Nathan Richardson

5-MeO-DMT Article Business Industry Research

August 21, 2026

PharmAla’s patent, asset-retention strategy, and Canaccord partnership signal a push toward commercial leadership in psychedelic therapeutics

briefglance.com · Aug 21, 2026 · Christine Carter

MDMA Article Business Industry Research

Compass Pathways builds a medical science liaison team to prepare commercial readiness for COMP360 psilocybin therapy ahead of possible regulatory approval

behavioralwire.com · Aug 21, 2026 · Behavioral Wire Staff

Psilocybin Article Business Industry Therapy

August 20, 2026

100-Mio.-Unternehmer über seine erste psychedelische Erfahrung | #25 Thorsten Gerber

youtube.com · Aug 20, 2026 · Thorsten Gerber

Psilocybin Interview Business Consciousness Integration DE

Big pharma targets psychedelic medicine as patent strategies, drug development costs, and mental health demand reshape a fast-growing commercial market

marketplace.org · Aug 20, 2026

Psilocybin MDMA Business Industry +2

Radial acquires Mindful Health Solutions to expand into brain medicine as consolidation and investor interest accelerate across behavioral health and psychedelics

bhbusiness.com · Aug 20, 2026 · Chris Larson

Article Business Industry Mainstream

TD Cowen raises Helius Medical Technologies price target to $6.20 as neurostimulation trial timing shifts and commercialization expectations remain under review

ca.investing.com · Aug 20, 2026

Business Industry

August 18, 2026

Johnson & Johnson is set to lead Delix Therapeutics' $85 million Series C, signaling major pharma backing for non-hallucinogenic neuroplastogens

psychedelicalpha.com · Aug 18, 2026 · Josh Hardman

Business Industry Research

August 6, 2026

Definium Therapeutics reports second quarter 2026 financial results, operational updates, and recent corporate highlights tied to its psychedelic medicine pipeline

businesswire.com · Aug 6, 2026

Business Industry

August 5, 2026

Compass Pathways announces employee inducement equity grants under Nasdaq Rule 5635(c)(4) for new hires at the psychedelic medicine company

businesswire.com · Aug 5, 2026

Business Industry

July 29, 2026

Eli Lilly is acquiring atai Beckley for $2.8 billion to add a late-stage psychedelic therapy pipeline centered on rapid-acting treatments for depression and other brain disorders

fool.com · Jul 29, 2026 · Alex Carchidi

Article Business Industry Therapy

Compass Pathways will report second quarter and first half 2026 financial results on August 5, with a conference call expected to update investors on its psilocybin therapy program

businesswire.com · Jul 29, 2026

Psilocybin Business Industry

July 24, 2026

The Psychedelic Inflection Point: Big Pharma, FDA, and the Next Wave of Brain Medicines

youtube.com · Jul 24, 2026 · Tim Gortman

Psilocybin DMT Podcast Business +4

Eli Lilly's acquisition of a psychedelic biotech turned founder Christian Angermayer's stake into a $360 million windfall and highlights pharma interest in mental health drug development

forbes.com · Jul 24, 2026 · Will Yakowicz

Article Business Industry Mainstream

July 22, 2026

Exclusive report traces why Eli Lilly partnered with atai Life Sciences on a ketamine-inspired pipeline, highlighting deuterated candidates, commercial fit, and strategic timing

illusionconsensus.com · Jul 22, 2026 · Rav Arora

Ketamine Business Industry Therapy